HC Wainwright Reiterates Neutral Rating for Poseida Therapeutics (NASDAQ:PSTX)

HC Wainwright restated their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note published on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock, down from their prior price target of $20.00.

Poseida Therapeutics Stock Up 228.0 %

Shares of NASDAQ PSTX opened at $9.38 on Tuesday. The company’s 50 day moving average price is $2.90 and its 200-day moving average price is $2.97. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. Poseida Therapeutics has a 52-week low of $1.87 and a 52-week high of $9.41. The company has a market capitalization of $914.17 million, a P/E ratio of -14.89 and a beta of 0.54.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC grew its stake in Poseida Therapeutics by 53.4% during the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the period. Vanguard Group Inc. grew its position in shares of Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares during the period. Public Employees Retirement System of Ohio lifted its position in shares of Poseida Therapeutics by 177.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after acquiring an additional 40,245 shares during the period. Lazard Asset Management LLC boosted its stake in Poseida Therapeutics by 280.3% during the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after acquiring an additional 21,138 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in Poseida Therapeutics in the first quarter worth $33,000. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.